BioCentury | Jul 3, 2006
Company News

Metabasis, Cengent deal

...protein tyrosine phosphatase 1B ( PTP-1B ) program for metabolic diseases from note holders of Cengent...
...other components of Cengent's PTP-1B program. Cengent note holders are eligible for milestones and royalties. Cengent...
...by Inncardio Inc. (INDO, New York, N.Y.) last year, but the acquisition was terminated and Cengent...
BioCentury | Jun 28, 2006
Company News

Metabasis buys Cengent's PTP-1B metabolic program

...protein tyrosine phosphatase 1B ( PTP-1B ) program for metabolic diseases from note holders of Cengent...
...other components of Cengent's PTP-1B program. Cengent note holders are eligible for milestones, plus royalties. Cengent...
BioCentury | Apr 18, 2005
Company News

Cengent, Inncardio deal

...an undisclosed sum. Cengent has Type II diabetes compounds that inhibit PTP-1B in lead optimization. Cengent Therapeutics Inc....
BioCentury | Nov 22, 2004
Company News

Cengent, Dynamis deal

...associated with complications of diabetes. Cengent will receive upfront payments and is eligible for milestones. Cengent Therapeutics Inc....
BioCentury | Nov 15, 2004
Company News

Cengent, Dynamis screening deal

...an enzyme that causes the formation of 3-deoxyglucosone, which is associated with complications of diabetes. Cengent...
BioCentury | May 31, 2004
Company News

MultiCell Technologies scientific advisory board update

...Inc. (EXTI), Warwick, R.I. Business: Gene/Cell therapy Appointed: Edward Maggio, CEO and a founder of Cengent Therapeutics Inc....
BioCentury | Apr 19, 2004
Company News

Cengent, Novartis deal

...targets identified by NVS. Cengent will receive an upfront payment and is eligible for milestones. Cengent Therapeutics Inc....
BioCentury | Apr 12, 2004
Company News

Cengent, Novartis discovery deal

...Genes to Leads lead identification technology to screen multiple targets identified by Novartis (NVS; SWX:NOVN). Cengent...
BioCentury | Mar 1, 2004
Company News

Cengent, The Center for Biophysical Sciences and Engineering deal

...The center will use its high throughput crystallography and Cengent will use its "Genes to Leads"...
...Cengent also will receive crystallographic support from the center for optimization of its own compounds. Cengent Therapeutics Inc....
BioCentury | Nov 24, 2003
Clinical News

Cengent preclinical data

...lethal factor partially restored anthrax lethal factor-suppressed immunological function. In rats, treatment significantly increased lifespan. Cengent Therapeutics Inc....
Items per page:
1 - 10 of 14
BioCentury | Jul 3, 2006
Company News

Metabasis, Cengent deal

...protein tyrosine phosphatase 1B ( PTP-1B ) program for metabolic diseases from note holders of Cengent...
...other components of Cengent's PTP-1B program. Cengent note holders are eligible for milestones and royalties. Cengent...
...by Inncardio Inc. (INDO, New York, N.Y.) last year, but the acquisition was terminated and Cengent...
BioCentury | Jun 28, 2006
Company News

Metabasis buys Cengent's PTP-1B metabolic program

...protein tyrosine phosphatase 1B ( PTP-1B ) program for metabolic diseases from note holders of Cengent...
...other components of Cengent's PTP-1B program. Cengent note holders are eligible for milestones, plus royalties. Cengent...
BioCentury | Apr 18, 2005
Company News

Cengent, Inncardio deal

...an undisclosed sum. Cengent has Type II diabetes compounds that inhibit PTP-1B in lead optimization. Cengent Therapeutics Inc....
BioCentury | Nov 22, 2004
Company News

Cengent, Dynamis deal

...associated with complications of diabetes. Cengent will receive upfront payments and is eligible for milestones. Cengent Therapeutics Inc....
BioCentury | Nov 15, 2004
Company News

Cengent, Dynamis screening deal

...an enzyme that causes the formation of 3-deoxyglucosone, which is associated with complications of diabetes. Cengent...
BioCentury | May 31, 2004
Company News

MultiCell Technologies scientific advisory board update

...Inc. (EXTI), Warwick, R.I. Business: Gene/Cell therapy Appointed: Edward Maggio, CEO and a founder of Cengent Therapeutics Inc....
BioCentury | Apr 19, 2004
Company News

Cengent, Novartis deal

...targets identified by NVS. Cengent will receive an upfront payment and is eligible for milestones. Cengent Therapeutics Inc....
BioCentury | Apr 12, 2004
Company News

Cengent, Novartis discovery deal

...Genes to Leads lead identification technology to screen multiple targets identified by Novartis (NVS; SWX:NOVN). Cengent...
BioCentury | Mar 1, 2004
Company News

Cengent, The Center for Biophysical Sciences and Engineering deal

...The center will use its high throughput crystallography and Cengent will use its "Genes to Leads"...
...Cengent also will receive crystallographic support from the center for optimization of its own compounds. Cengent Therapeutics Inc....
BioCentury | Nov 24, 2003
Clinical News

Cengent preclinical data

...lethal factor partially restored anthrax lethal factor-suppressed immunological function. In rats, treatment significantly increased lifespan. Cengent Therapeutics Inc....
Items per page:
1 - 10 of 14